TheraSonic develops a non-invasive device that transiently disrupts the blood-brain barrier using low-intensity focused ultrasound. This technology facilitates the targeted delivery of therapeutics to specific locations within the brain for treating neurological disorders. The platform ensures safety and accuracy through real-time dosimetry and neuro-navigation, enabling treatment of multiple targets in a single session.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The blood-brain barrier (BBB) presents a significant obstacle to treating neurological disorders, as it selectively restricts the delivery of therapeutic agents to the brain. Current methods to bypass this barrier are often invasive and lack precise targeting capabilities.
Solution
TheraSonic is developing a non-invasive focused ultrasound device designed to transiently disrupt the blood-brain barrier, enabling targeted delivery of therapeutics to specific areas within the brain. The device utilizes low-intensity focused ultrasound to facilitate the passage of drugs across the BBB with enhanced precision. Real-time dosimetry ensures the safe disruption of the BBB, allowing for repeated treatments. A state-of-the-art neuro-navigation solution ensures accurate targeting of the desired brain regions, while the platform's medical robot technology enables treatment of multiple targets and large volumes in a single session.
Target Audience
The primary audience includes medical professionals and researchers focused on treating neurological disorders who require a non-invasive method for targeted drug delivery to the brain.
Features
- Non-invasive focused ultrasound technology for transiently disrupting the blood-brain barrier
- Real-time dosimetry solution to ensure safe and repeatable BBB disruption
- Neuro-navigation solution for precise targeting within the brain
- Medical robot technology for treating multiple targets and large volumes